Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised study for double-blind, placebo-controlled evaluation of BI 765845 on top of standard of care in patients with myocardial infarction
2022-502788-39-00Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2023
- Modality
- Small Molecules
- Countries
- 16
01
Overview
Phase 2, randomised, double-blind trial in myocardial infarction (MI) comparing BI 765845 + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Infarct severity. Started Oct 2023; status: completed.
02
Drugs
BI 765845
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on 2022-502788-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502788-39-00.